A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Signed written informed consent * Cytologically or histologically confirmed NSCLC * Clinical or radiographic progression during or after first-line chemotherapy or chemoradiotherapy for NSCLC * Consent to provide archival tissue for analysis is required for participation in this study * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Age ≥ 18 years * Use of an acceptable means of contraception for men and women of childbearing potential * International normalized ratio (INR) no greater than 1.3 and an aPTT no greater than the upper limits of normal within 28 days prior to enrollment for patients not on low-molecular-weight heparin or fondaparinux Exclusion Criteria: * Squamous cell carcinoma * Prior treatment with an investigational or marketed inhibitor of the Epidermal Growth Factor Receptor (EGFR) pathway or anti-angiogenesis agent * Systemic chemotherapy, radiotherapy, or investigational treatment within 28 days prior to randomization * Local palliative radiotherapy within 14 days prior to randomization or persistent adverse effects from radiotherapy that have not resolved to Grade 2 or less following completion of treatment * Whole brain radiotherapy or stereotactic radiosurgery for brain metastases within 4 weeks of Day 0 * Neurosurgery for brain metastases within 24 weeks of Day 0 * Brain biopsy within 12 weeks of Day 0 * Current use of dexamethasone for treatment associated with brain metastases * History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation * History of any of the following within 6 months prior to Day 0: serious systemic disease, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess * Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization * Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months * Progressive neurologic symptoms in patients with a history of brain metastases * Full-dose anticoagulation with warfarin * Chronic daily use of aspirin or other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-platelet activity * In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization * Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization * Anticipation of need for a major surgical procedure during the course of the study * Serious, non-healing wound, ulcer, or bone fracture * Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption * Pregnancy or breast-feeding * Presence of another invasive cancer within 5 years prior to randomization * Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form or their ability to comply with study requirements